Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic Alternatives

Results from Cohorts 1 and 2 Showed a Dose-Dependent Reduction in Total Homocysteine Levels
Results from Cohort 3 Indicated Additional Dose Exploration and Data from Longer Treatment Duration May... | April 12, 2023

Related Keywords

Texas ,United States ,Linda Neuman ,Aeglea Biotherapeutics ,Jeffrey Goldberg ,Cortney Caudill ,Michaelc Hanley ,Aeglea Biotherapeutics Inc ,Exchange Commission ,Wedbush Securities Inc ,Company Annual Report On Form ,Nasdaq ,European Medicines Agency ,Dose Dependent Reduction ,Total Homocysteine Levels ,Additional Dose Exploration ,Longer Treatment Duration May ,Percent Change ,Total Homocysteine ,Baseline After ,Post Dose ,Explore Strategic ,Wedbush Securities ,Middle East ,Immedica Pharma ,Marketing Authorization Application ,Classical Homocystinuria ,Drug Designation ,Pediatric Disease ,Fast Track ,European Medicines ,Securities Litigation Reform Act ,Annual Report ,United States Securities ,Nc Stock Exchange ,News ,Information ,Press Release ,Results ,Rom ,Cohorts , ,End ,Howed ,Reduction ,N ,Total ,Homocysteine ,Levels ,Cohort ,Syndicated ,Dditional ,Nose ,Exploration ,Data ,Longer ,Treatment ,Uration Agle Us00773j1034 ,